Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Syngene's collaboration with Zoetis started in 2011
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Dupixent peak sales ambition raised to more than €13 billion
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Laglo Soft lotion comes with a unique technology that enhances moisturisation and restructures the skin
Subscribe To Our Newsletter & Stay Updated
